Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal Receptors

ClinicalTrials.gov ID: NCT02162719

Public ClinicalTrials.gov record NCT02162719. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 5:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Phase II, Multi-Center, Placebo-Controlled Study of Ipatasertib (GDC-0068), an Inhibitor of Akt, in Combination With Paclitaxel as Front-Line Treatment for Patients With Metastatic Triple-Negative Breast Cancer

Study identification

NCT ID
NCT02162719
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Genentech, Inc.
Industry
Enrollment
124 participants

Conditions and interventions

Interventions

  • Ipatasertib Drug
  • Paclitaxel Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 18, 2014
Primary completion
Jun 6, 2016
Completion
Aug 30, 2019
Last update posted
Mar 9, 2021

2014 – 2019

United States locations

U.S. sites
17
U.S. states
12
U.S. cities
16
Facility City State ZIP Site status
St Jude Heritage Medical Group Fullerton California 92835
Cedars Sinai Medical Center Los Angeles California 90048
Cancer Care Assoc Med Group Los Angeles California 90095-1772
UCLA Medical Center Santa Monica California 90404
Holycross Medical Group Fort Lauderdale Florida 33308
Memorial Healthcare System Hollywood Florida 33021
Hematology Oncology Associates of the Treasure Coast Port Saint Lucie Florida 34952
Rush University Medical Center Chicago Illinois 60612
Cancer Center of Kansas Wichita Kansas 67214-3728
Massachusetts General Hospital Cancer Center Boston Massachusetts 02114
Comprehensive Cancer Centers of Nevada Henderson Nevada 89014
Carolinas Healthcare System Charlotte North Carolina 28208
The WEST CLINIC, P.C. Memphis Tennessee 38119
MD Anderson Cancer Center Houston Texas 77030
Northern Utah Associates Ogden Utah 84403
Northwest Medical Specialties Lakewood Washington 98499
West Virginia University Hospitals Inc Morgantown West Virginia 26056

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 27 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02162719, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 9, 2021 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02162719 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →